NTLA Competitors & Alternatives
Compare Intellia Therapeutics Inc with similar stocks in the same industry
Biotechnology
NTLA
Main Stock$10.00
+3.09%
Tradestie Score
49
Market Cap
$2.01B
Revenue Growth
-48.0%
Analyst Upside
+127.8%
Supply-Chain & Ecosystem Map (Customers, Suppliers & Direct Competitors)
Bottleneck Score: 6/10
Genomics Precision Med
Gene Editing
Top Competitors
217 stocks in Biotechnology| Company | Price | Market Cap | P/E | Score | Action |
|---|---|---|---|---|---|
|
VCEL
Vericel Corporation
|
$57.27
+0.54%
|
$1.56B | 90.3 | 35 | Compare |
|
DNTH
Dianthus Therapeutics, Inc. Common Stock
|
$88.58
-3.52%
|
$1.55B | - | 32 | Compare |
|
HRMY
Harmony Biosciences Holdings, Inc. Common Stock
|
$33.13
-1.87%
|
$1.55B | 11.2 | 57 | Compare |
|
PHVS
Pharvaris N.V. Ordinary Shares
|
$32.61
-2.25%
|
$1.55B | - | 44 | Compare |
|
NVAX
Novavax Inc
|
$8.03
-5.81%
|
$1.54B | - | 55 | Compare |
|
AUPH
Aurinia Pharmaceuticals Inc
|
$15.48
-1.62%
|
$1.50B | 7.0 | 56 | Compare |
|
GPCR
Structure Therapeutics Inc. American Depositary Shares
|
$18.67
-6.65%
|
$1.50B | - | 42 | Compare |
|
AMLX
Amylyx Pharmaceuticals, Inc. Common Stock
|
$28.24
-6.78%
|
$1.49B | - | 52 | Compare |
|
RCUS
Arcus Biosciences, Inc.
|
$16.97
-2.64%
|
$1.43B | - | 43 | Compare |
|
JANX
Janux Therapeutics, Inc. Common Stock
|
$10.89
-4.22%
|
$1.42B | - | 45 | Compare |
More NTLA Analysis
Data updated: Nov 16, 2026 | Industry: Biotechnology (SIC 2835)
217 stocks in this industry